Work

PS5-09-15: ERADICATE: A phase Ib/II study of elacestrant plus trastuzumab deruxtecan in patients with CDK4/6 inhibitor and endocrine-resistant HR+/HER2-low or HER2-ultralow metastatic breast cancer

Year: 2026

Type: article

Source: Clinical Cancer Research

DOI: 10.1158/1557-3265.sabcs25-ps5-09-15

Authors: S. Sammons, S. Tolaney, N. Lin, L. Anderson, E. Mayer, N. Sinclair, J. Stoeckle, P. Sanz-Altamira, N. Graham, R. Jeselsohn

Institution: Dana-Farber Cancer Institute

Language: English

Topic: Advanced Breast Cancer Therapies

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W7129303595

FWCI:

Cites:

Cited by:

Related to: